BD (Becton, Dickinson and Company) has launched a high-throughput diagnostic system using robotics and sample management software algorithms.
The BD COR PX/GX System has been in use in Europe since 2019 through a CE-mark and is now approved by the U.S. Food and Drug Administration (FDA) for use in the United States.
The BD COR System will be initially available with the BD Onclarity HPV Assay with extended genotyping that detects 14 high-risk (HR) HPV types in a single analysis. Persistent infection with human papillomavirus (HPV) is one of the primary causes of cervical cancer.
The system enables the processing of samples directly from liquid-based cytology vials, the creation of molecular aliquot tubes and assay testing. The BD COR PX instrument will prepare the samples by performing the appropriate pre-analytical processing steps and automatically deliver the samples to the BD COR GX instrument for analysis. The GX instrument will perform the analytical steps of the BD Onclarity HPV Assay, including extraction, amplification, and detection.
